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Abstract
We report a successful case of living-donor lobar lung transplantation (LDLLT) for therapy-resistant broncho-bronchiolitis
obliterans (BBO) after allogeneic hematopoietic stem cell transplantation (HSCT). Bronchiolitis obliterans (BO) is one of the
late-onset noninfectious pulmonary complications that occur after allogeneic HSCT and is usually resistant to immunosup-
pressive therapy. A 17-year-old girl with acute lymphoblastic leukemia (ALL) had undergone allogeneic bone marrow
transplantation (BMT) from an HLA-matched sibling in 1997. Five years later, she relapsed with ALL and was treated with
chemotherapy following stem cell rescue and donor lymphocyte infusion from the original BMT donor. Eight months later,
BBO resistant to immunosuppressive therapies, including rituximab, developed in combination with chronic graft-versus-host
disease (GVHD). In February 2004, the patient underwent LDLLT from 2 other family members who were mismatched at 3
HLA loci. The patient has been in good health for more than 30 months following LDLLT and shows no sign of BBO in the
transplanted lungs, just as with other patients who have undergone lung transplantation for BO associated with chronic GVHD.
LDLLT may therefore be considered a viable therapeutic option for the treatment of BO after allogeneic HSCT.
Int J Hematol. 2007;86:xxx-xxx. doi: 10.1532/IJH97.07045
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Case Report
1. Introduction
Pulmonary complications develop in 40% to 60% of
recipients of allogeneic hematopoietic stem cell transplanta-
tion (HSCT) [1-3]. In 1998, Palmas et al [4] defined
noninfectious pulmonary complications that occur later than
3 months after allogeneic SCT as late-onset noninfectious
pulmonary complications (LONIPCs). Once LONIPCs
occur, the recipient’s quality of life is markedly impaired;
therefore, LONIPCs are recognized as a major cause of mor-
bidity and mortality after allogeneic HSCT [4,5]. LONIPCs
include bronchiolitis obliterans (BO), bronchiolitis obliter-
ans with organizing pneumonia (BOOP), diffuse alveolar
damage, lymphocytic interstitial pneumonia (LIP), and
nonclassifiable interstitial pneumonia (NCIP) [4]. Although
the pathogenesis of LONIPCs remains unclear, LONIPCs
are strongly associated with chronic graft-versus-host disease
(GVHD) [4,6,7]. Immunosuppressive therapies have been
considered to be the standard treatments for LONIPCs. In
fact, LIP, NCIP, and BOOP have all been shown to success-
fully respond to these treatments [4,7]. BO, however, is
usually resistant to such treatments [4,7,8].The mortality rate
for BO following allogeneic HSCT therefore may be as high
as 100% [1,9,10].
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Lung transplantation (LT) is an alternative therapeutic
option for BO in some selected patients; however, the long-
term efficacy of LT for BO and the recurrence rate of BO
in transplanted lungs are unknown. We describe a patient
who underwent living-donor lobar LT (LDLLT) for therapy-
resistant BO after allogeneic HSCT and who has demon-
strated no disease recurrence for more than 30 months after
LDLLT.
2. Case Report
A 17-year-old girl received a diagnosis of acute
lymphoblastic leukemia (ALL) in February 1997. She was
treated with combination chemotherapy [11] and obtained
complete remission. The patient underwent allogeneic bone
marrow transplantation from her HLA-matched sibling in
July 1997. The preconditioning regimen consisted of 3 Gy
total body irradiation once daily for 4 consecutive days (total
dose, 12 Gy), 2 g/m2 cytarabine administered intravenously
twice daily for 2 consecutive days (total, 4 doses), and
60 mg/kg cyclophosphamide administered intravenously
once daily for 2 consecutive days (total dose, 120 mg/kg).
GVHD prophylaxis consisted of cyclosporine (CsA) and
short-term methotrexate. No GVHD was observed, and CsA
was tapered off until February 1998. The patient relapsed
with ALL in October 2002. An anthracycline-containing reg-
imen [11] induced a second complete remission. Eight days
after consolidation therapy consisting of 2 g/m2 cytarabine
administered intravenously twice daily for 5 consecutive
days (total, 10 doses), the patient received donor buffy coat
containing 5.4  106/kg CD34+ cells and 0.7  108/kg CD3+ cells,
which were collected after administration of granulocyte
colony-stimulating factor. No GVHD prophylaxis was given.
Because GVHD did not develop until day 70 after the buffy
coat infusion, the patient received donor leukocyte infusions
at a dose of 0.7  108/kg of CD3+ cells on day 34 and 1.4  108/kg
on day 70 after the buffy coat infusion. In March 2003,
10 days after receiving the second donor lymphocyte infu-
sion, the patient developed lichenoid lesions and ulcers on
the buccal mucosa and eruptions on the skin. A lip biopsy
revealed pathologic changes compatible with chronic
GVHD. Oral administration of CsA was initiated in April
2003. The lichenoid lesions of the buccal mucosa gradually
improved, but the symptoms of dry eyes and skin eruptions
did not improve. In April 2003, the patient began complain-
ing of dry cough, which gradually worsened. She was
hospitalized in August 2003 because of an exacerbation of
dry cough and dyspnea. A computed tomography examina-
tion of the chest showed atelectases of the right lower lobes,
diffuse parenchymal hypoattenuation, and proximal
bronchiectases. Her forced vital capacity (FVC) and forced
expiratory volume in 1 second (FEV1.0) had also decreased
markedly (Figure 1). A bronchofiberscopy examination
showed obstructions at the level of the broncho-bronchiols,
predominantly in the lower lobes on both sides. The patient
then received a diagnosis of broncho-bronchiolitis obliterans
(BBO), a variant of BO. The CsA dose was increased, and
oral administration of prednisolone was initiated; however,
no response was observed. As the patient’s symptoms
worsened, CsA was replaced with tacrolimus. In addition,
rituximab was administered at 375 mg/m2 once a week for 4
weeks to treat scleroderma caused by the chronic GVHD
[12]. We concluded that scleroderma had partially
contributed to her constrictive respiratory failure by limiting
chest wall compliance; however, the patient’s respiratory
failure associated with hypercapnia became exacerbated to
such a degree that she became completely dependent on
oxygen support. The patient became totally bedridden and
had to undergo a tracheostomy in January 2004 to receive
mechanical ventilation. At this time, her family requested
that LT be performed. The patient was considered a candi-
date for LDLLT because she had end-stage BO (which is
listed as a clinical status meeting the indication criteria for
LT), because of the impossibility of waiting for a cadaveric
lung graft owing to her rapid exacerbation of respiratory
failure, and because there were no contraindications for LT
except for the coexistence of malignant disease [13,14]. The
patient’s ALL had been in the second complete remission for
more than a year, however, and the level of Wilms tumor
gene in the bone marrow was 120 copies/μg RNA, thus
indicating a low potential for an ALL relapse [15].The ethics
committee of the lung-transplantation center approved
LDLLT for this patient because she was considered to have
neither newly treated malignant disease nor widespread
malignancy. LDLLT was performed on February 16, 2004,
with a right lower lobe from her older brother (who was
mismatched at 3 HLA loci in the direction of graft rejection)
and a left lower lobe from her mother, who was mismatched
at 3 antigens in the direction of graft rejection (Table 1). The
patient’s own lungs were removed completely. The ABO
antigens of the recipient and donors were compatible
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Figure 1. The pulmonary function test before and after living-donor
lobar lung transplantation. FVC indicates forced vital capacity; FEV1.0,
forced expiratory volume in 1 second.
Table 1.
HLA of the Patient and Donors*
A B DR
Recipient 11/24 52/– 9/15
HSCT donor (younger brother) 11/24 52/– 9/15
LDLLT donor (elder brother) 2/11 46/52 8/15
LDLLT donor (mother) 2/11 13/52 12/15
*HSCT indicates hematopoietic stem cell transplantation; LDLLT,
living-donor lobar lung transplantation.































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(Table 1). The immunosuppressive therapy to prevent graft
rejection consisted of tacrolimus, prednisolone, and azathio-
prine. Signs of acute rejection appeared after LDLLT, but
rejection was successfully avoided by the intravenous admin-
istration of methylprednisolone and mycophenolate mofetil.
The hypercapnia rapidly improved, and the vital capacity
increased immediately after LDLLT. This progress allowed
the patient to be weaned from mechanical ventilation on
day 15, and she was discharged from the hospital on day 64
after LDLLT. BBO has not recurred in the transplanted
lungs, and tests of pulmonary function have shown improve-
ments in both the FVC and FEV1.0 for more than 30 months
following LDLLT, despite the persistence of dry eyes and
impaired lacrimal secretion.A pathologic examination of the
explanted lungs revealed focal desquamation of the
broncho-bronchiolar epithelium with an aggregate of foamy
macrophages and lymphocytes and occlusions of the
broncho-bronchiolar lumen, observations compatible with a
diagnosis of either BBO or BO [16].
3. Discussion
BO is one of the LONIPCs and occurs 3 to 15 months
following allogeneic HSCT [4,5,7,8]. The clinical symptoms
of BO include a nonproductive cough, rapidly progressive
dyspnea, and wheezing. The incidence of BO following
allogeneic HSCT varies from 2.7% to 7.6% according to the
published studies [4,7,8]. BO is one of the most devastating
complications of allogeneic HSCT. Once it occurs in a
patient, the prognosis tends to be extremely poor. The
mortality rate reportedly varies from 14% to 100% [7,17,18].
The response to BO treatment has a significant effect on
survival: 79% of responders survived more than 5 years from
the diagnosis of BO, but only 13% of nonresponders
survived [8]. Patients with LONIPCs have been treated with
immunosuppressive agents such as antithymocyte globulin,
methylprednisolone, prednisolone, CsA, tacrolimus, and
azathioprine. Most patients with LIP and BOOP responded
well to such treatments, whereas only 16% to 49% of BO
patients improved owing to these treatments [4,7,8].
Consequently, no standard therapy for BO has yet been
established.
Because BO often develops in association with chronic
GVHD, this complication is thought to be one of the
pulmonary manifestations of chronic GVHD [7,8,19].
However, the development of BO following autologous bone
marrow transplantation in 2 patients [20] and a lower
incidence of BO in recipients of allogeneic HSCT following
reduced-intensity conditioning than in HSCT recipients with
myeloablative conditioning [21] suggest that tissue damage
due to high-dose radiochemotherapy plays a role in the
development of BO. Our patient had extensive chronic
GVHD, as manifested by sicca symptoms, at the time of
LDLLT, and these symptoms persisted for more than 30
months, even after LDLLT. Because her lungs were
suspected to be a target of the chronic GVHD, an LT from
the donor of the allogeneic HSCT was thought to be ideal;
however, because the donor and patient’s family did not
consent, she received an LT from 2 family members who
were mismatched at 3 HLA loci. Despite the presence of
HLA mismatches between the lung donors and the patient
and the persistence of chronic GVHD, there has been no
recurrence of BO in the transplanted lungs.
Fifteen cases of LT for post-SCT pulmonary complications
following allogeneic HSCT, including 10 BO patients, have
been reported (Table 2) [22-29]. The indications for LT in
patients demonstrating BO following allogeneic HSCT are
limited by many factors, such as the criteria of the donor and
recipient, the existence of a suitable donor, the status of
hematologic disease, and the timing of LT, especially for
LDLLT [30]. Four of the 10 BO patients died after LT
[24,27,29]. The patient in case 7 died of chronic rejection
6 years after undergoing LT, patient 11 died of pulmonary
hemorrhaging 3 weeks after receiving LT, and patient 3, who
received a single LT from a cadaver, died of BO on day 271,
following recurrent episodes of both perivascular and
bronchial rejection. Pechet et al [29] described 2 patients who
had complications of BO long after LT; however, the authors
did not report the details of these patients. The development
of post-LT BO was thought to be due in part to a manifesta-
tion of chronic rejection [31,32]; however, preexisting chronic
GVHD may have played some role in the development of
BO in the transplanted lung early after transplantation. The
other 5 BO patients (except for those described by Pechet
et al [29]) and our patient have not experienced BO in the
transplanted lungs from more than 15 months to 6 years after
LT, despite the existence of chronic GVHD. These findings
indicate that factors other than chronic GVHD, such as high-
dose chemoradiotherapy and viral infections, may contribute
to the development of BO following allogeneic HSCT.
Another possibility is that the development of BO may
require the presence of specific minor histocompatibility anti-
gen (mHa) mismatches between the donor of the LT and the
patient’s immune system. The transplanted lungs may have
evaded the immune attack responsible for BO because of a
lack of mHas mismatches. LT is therefore considered to be a
promising therapy for BO, even for patients associated with
active chronic GVHD.
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